Trend
DailyUptrend (starting)
4 hourExpanding
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns down below $31.67
Key levels
Resistance$36.63
Resistance$34.72
Support$31.81
Support$28.72
Latest news & SEC filings
ProductCastle Biosciences to Present New Data on DecisionDx-Melanoma
AnalystBaird Increases Castle Biosciences Price Target
AnalystBaird keeps Outperform rating on Castle Biosciences, lifts target to $41
All CSTL news →This company develops laboratory tests that analyze gene activity to help doctors diagnose and treat certain cancers and other conditions. Its offerings include tests for melanoma, squamous cell skin cancer, difficult-to-diagnose skin lesions and ocular melanoma, plus a test for Barrett's esophagus and one for guiding treatment of atopic dermatitis. It runs clinical labs in Arizona and Pennsylvania and sells mainly to dermatologists, gastroenterologists and eye specialists across the United States. Payments come largely from Medicare and private health insurers.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
SEPT Low Target
$40.00
SEPT Mid Target
$41.50
SEPT High Target
$44.00
Analyst Consensus
$41.50
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CSTL.
Start Free Trial →Valuation Verdict
FAIR
Methods Used
P/B, Analyst Consensus
Fair Value
$41.23
25
Moat Score
NONE
3/9
Piotroski Score
6.2
Altman Z-Score
Insider Signal
SELLING
0 buys / 18 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| MAETZOLD DEREK J | director officer | Sale | 7,555 | $272K | Nov 2, 2026 |
| MAETZOLD DEREK J | director officer | Sale | 2,816 | $101K | Nov 2, 2026 |
| MAETZOLD DEREK J | director officer | Sale | 2,393 | $86K | Nov 2, 2026 |
| MAETZOLD DEREK J | director officer | Sale | 1,025 | $38K | Nov 2, 2026 |
| MAETZOLD DEREK J | director officer | Sale | 382 | $14K | Nov 2, 2026 |
| MAETZOLD DEREK J | director officer | Sale | 325 | $12K | Nov 2, 2026 |
| Juvenal Tobin W | officer | Sale | 1,237 | $44K | Oct 28, 2026 |
| Juvenal Tobin W | officer | Sale | 5,341 | $196K | Oct 28, 2026 |
| Juvenal Tobin W | officer | Sale | 3,288 | $109K | Oct 26, 2026 |
| MAETZOLD DEREK J | director officer | Sale | 8,580 | $274K | Oct 19, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
3.7%
3yr Revenue CAGR
35.9%
EPS Growth YoY
-233.87%
FCF Growth YoY
-22.5%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for CSTL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:40 | $34.50 | 2,224 | $$77K | BUY |
| 21:00:01 | $34.50 | 2,243 | $$77K | BUY |
| 20:44:37 | $34.56 | 1,000 | $$35K | MIDPOINT |
| 20:24:19 | $34.15 | 3,619 | $$124K | SELL |
| 19:58:07 | $34.16 | 5,062 | $$173K | BUY |
5 dark pool trades shown · $$485K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for CASTLE BIOSCIENCES INC (CSTL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CASTLE BIOSCIENCES INC (CSTL) is at $34.49, up 1.47% (+$0.50) at the Nov 12, 2026 close.
Latest CSTL news — Nov 11, 2026: Castle Biosciences to Present New Data on DecisionDx-Melanoma · Nov 9, 2026: Baird Increases Castle Biosciences Price Target
The average analyst price target for CSTL is $41.50, ranging from $40 to $44, based on 4 analysts. Latest: BTIG maintains on Aug 3, 2026.
Analyst ratings for CSTL: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
CSTL last reported on Nov 5, 2026: EPS -$0.13 vs -$0.35 expected — a beat of 62.6%.
CSTL does not currently pay a dividend.
CASTLE BIOSCIENCES INC reported $10M of debt and $62M of cash (Jun 30, 2026).
Support: $31.81, $28.72, $25.63. Resistance: $34.72, $36.63, $38.73.
Insider activity: SELLING, 0 buys and 18 sells in the last 90 days.
Nov 11, 2026: Castle Biosciences to Present New Data on DecisionDx-Melanoma · Nov 9, 2026: Baird Increases Castle Biosciences Price Target · Nov 9, 2026: Baird keeps Outperform rating on Castle Biosciences, lifts target to $41